[
  {
    "ts": null,
    "headline": "Biogen (BIIB): Revisiting Valuation After Recent Pipeline and Partnership Developments",
    "summary": "Biogen (BIIB) shares have edged lower in recent days, as investors watch closely for updates on its product pipeline and ongoing partnerships. The stock has moved slightly during the past week, prompting some to revisit its current valuation. See our latest analysis for Biogen. The recent dip in Biogen’s share price follows a period of wider volatility. The bigger picture is clear: the stock’s momentum has cooled, with a 1-year total shareholder return of -22.2% and an even steeper three-year...",
    "url": "https://finnhub.io/api/news?id=28bf24751dc6ef0e607f99dd976576e41d939c00b9295dadec818c6a305f37a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760288892,
      "headline": "Biogen (BIIB): Revisiting Valuation After Recent Pipeline and Partnership Developments",
      "id": 137063913,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (BIIB) shares have edged lower in recent days, as investors watch closely for updates on its product pipeline and ongoing partnerships. The stock has moved slightly during the past week, prompting some to revisit its current valuation. See our latest analysis for Biogen. The recent dip in Biogen’s share price follows a period of wider volatility. The bigger picture is clear: the stock’s momentum has cooled, with a 1-year total shareholder return of -22.2% and an even steeper three-year...",
      "url": "https://finnhub.io/api/news?id=28bf24751dc6ef0e607f99dd976576e41d939c00b9295dadec818c6a305f37a2"
    }
  }
]